MiR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3ζ

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Jung, Hyun M ^a   Phillips, Brittany L ^a   Chan, Edward K L ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

E6AP; Human papillomavirus; MicroRNA; miR 375; p21; Telomerase

Indexed keywords

CELL PROTEIN; CIP2A PROTEIN; E6 ASSOCIATED PROTEIN; MICRORNA 375; MYC PROTEIN; PROTEIN 14 3 3; PROTEIN E6; PROTEIN E7; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; AUTOANTIGEN; DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; MICRORNA; MIRN375 MICRORNA, HUMAN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UBE3A PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOFLUORESCENCE; LOSS OF FUNCTION MUTATION; LUCIFERASE ASSAY; NONHUMAN; OROPHARYNX CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TRANSIENT TRANSFECTION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRUS TRANSCRIPTION; WART VIRUS; WESTERN BLOTTING; BIOSYNTHESIS; GENETICS; METABOLISM; TUMOR CELL LINE;

HUMAN PAPILLOMAVIRUS;

14-3-3 PROTEINS; AUTOANTIGENS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MEMBRANE PROTEINS; MICRORNAS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; RETINOBLASTOMA PROTEIN; RHO GTP-BINDING PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84899487649     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-80     Document Type: Article

References (91)

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233. 10.1016/j.cell.2009.01.002, 3794896, 19167326.
2. Reczko M, Maragkakis M, Alexiou P, Grosse I, Hatzigeorgiou AG. Functional microRNA targets in protein coding sequences. Bioinformatics 2012, 28:771-776. 10.1093/bioinformatics/bts043, 22285563.
3. Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, Chang LJ, Yang LJ, Chan EK. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell 2013, 24:1638-1648. 10.1091/mbc.E12-12-0891, 3667718, 23552692.
4. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105. 2612969, 18955434.
5. zur Hausen H, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol 1994, 48:427-447. 10.1146/annurev.mi.48.100194.002235, 7826013.
6. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113:3036-3046. 10.1002/cncr.23764, 18980286.
7. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, Yankey D, Edwards BK. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013, 105:175-201. 10.1093/jnci/djs491, 3565628, 23297039.
8. Chang YE, Laimins LA. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 2000, 74:4174-4182. 10.1128/JVI.74.9.4174-4182.2000, 111932, 10756030.
9. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 2001, 75:4283-4296. 10.1128/JVI.75.9.4283-4296.2001, 114174, 11287578.
10. Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999, 259:305-313. 10.1006/viro.1999.9771, 10388655.
11. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998, 12:2061-2072. 10.1101/gad.12.13.2061, 316980, 9649509.
12. Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol 2009, 19:97-113. 10.1002/rmv.605, 19156753.
13. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482.
14. Syrjanen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol 2010, 21(Suppl 7):vii243-vii245.
15. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002, 89:213-228. 10.1016/S0168-1702(02)00190-9, 12445661.
16. Blackburn EH. Switching and signaling at the telomere. Cell 2001, 106:661-673. 10.1016/S0092-8674(01)00492-5, 11572773.
17. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, Wu JR. A highly conserved repetitive DNA sequence, (TTAGGG) n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 1988, 85:6622-6626. 10.1073/pnas.85.18.6622, 282029, 3413114.
18. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460. 10.1038/345458a0, 2342578.
19. Vaziri H, Schachter F, Uchida I, Wei L, Zhu X, Effros R, Cohen D, Harley CB. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 1993, 52:661-667. 1682068, 8460632.
20. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001, 107:67-77. 10.1016/S0092-8674(01)00504-9, 11595186.
21. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015. 10.1126/science.7605428, 7605428.
22. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996, 380:79-82. 10.1038/380079a0, 8598912.
23. Granger MP, Wright WE, Shay JW. Telomerase in cancer and aging. Crit Rev Oncol Hematol 2002, 41:29-40. 10.1016/S1040-8428(01)00188-3, 11796230.
24. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, Moriyama M. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 2010, 70:2339-2349. 10.1158/0008-5472.CAN-09-2777, 20215506.
25. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006, 126:1203-1217. 10.1016/j.cell.2006.07.031, 16990141.
26. del Moral-Hernandez O, Lopez-Urrutia E, Bonilla-Moreno R, Martinez-Salazar M, Arechaga-Ocampo E, Berumen J, Villegas-Sepulveda N. The HPV-16 E7 oncoprotein is expressed mainly from the unspliced E6/E7 transcript in cervical carcinoma C33-A cells. Arch Virol 2010, 155:1959-1970. 10.1007/s00705-010-0787-9, 20865289.
27. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20. 10.1016/j.cell.2004.12.035, 15652477.
28. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A 1991, 88:5523-5527. 10.1073/pnas.88.13.5523, 51909, 1648218.
29. Crook T, Wrede D, Tidy J, Scholefield J, Crawford L, Vousden KH. Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Oncogene 1991, 6:1251-1257.
30. Dai M, Clifford GM, le Calvez F, Castellsague X, Snijders PJ, Pawlita M, Herrero R, Hainaut P, Franceschi S. Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res 2004, 64:468-471. 10.1158/0008-5472.CAN-03-3284, 14744758.
31. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75:495-505. 10.1016/0092-8674(93)90384-3, 8221889.
32. Iaquinta PJ, Lees JA. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007, 19:649-657. 10.1016/j.ceb.2007.10.006, 2268988, 18032011.
33. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996, 56:4620-4624.
34. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2:103-112. 10.1016/S1535-6108(02)00102-2, 12204530.
35. Du W, Searle JS. The rb pathway and cancer therapeutics. Curr Drug Targets 2009, 10:581-589. 10.2174/138945009788680392, 3151466, 19601762.
36. Niculescu AB, Chen X, Smeets M, Hengst L, Prives C, Reed SI. Effects of p21 (Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998, 18:629-643. 121530, 9418909.
37. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grenman R, Kast J, Kallunki T, Sears R, Kahari VM, Westermarck J. CIP2A inhibits PP2A in human malignancies. Cell 2007, 130:51-62. 10.1016/j.cell.2007.04.044, 17632056.
38. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, Tyner AL. Myc represses the p21 (WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A 2001, 98:4510-4515. 10.1073/pnas.081074898, 31865, 11274368.
39. Ceballos E, Munoz-Alonso MJ, Berwanger B, Acosta JC, Hernandez R, Krause M, Hartmann O, Eilers M, Leon J. Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells. Microarray analysis reveals defective induction of p53 target genes and upregulation of chaperone genes. Oncogene 2005, 24:4559-4571. 10.1038/sj.onc.1208652, 15856024.
40. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999, 13:2658-2669. 10.1101/gad.13.20.2658, 317106, 10541552.
41. Ceballos E, Delgado MD, Gutierrez P, Richard C, Muller D, Eilers M, Ehinger M, Gullberg U, Leon J. c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells. Oncogene 2000, 19:2194-2204. 10.1038/sj.onc.1203541, 10822369.
42. Lee EY, To H, Shew JY, Bookstein R, Scully P, Lee WH. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 1988, 241:218-221. 10.1126/science.3388033, 3388033.
43. Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JT, Gudas JM, Bates SE. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ 1995, 6:1395-1403.
44. Aguda BD, Kim Y, Kim HS, Friedman A, Fine HA. Qualitative network modeling of the Myc-p53 control system of cell proliferation and differentiation. Biophys J 2011, 101:2082-2091. 10.1016/j.bpj.2011.09.052, 3207173, 22067145.
45. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, Dalla-Favera R. Direct activation of TERT transcription by c-MYC. Nat Genet 1999, 21:220-224. 10.1038/6010, 9988278.
46. Kusumoto M, Ogawa T, Mizumoto K, Ueno H, Niiyama H, Sato N, Nakamura M, Tanaka M. Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells. Clin Cancer Res 1999, 5:2140-2147.
47. Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H, Inoue M. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 2000, 6:1239-1247.
48. Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D, Rotter V. p53-dependent down-regulation of telomerase is mediated by p21waf1. J Biol Chem 2004, 279:50976-50985. 10.1074/jbc.M402502200, 15371422.
49. Crowe DL, Nguyen DC. Rb and E2F-1 regulate telomerase activity in human cancer cells. Biochim Biophys Acta 2001, 1518:1-6. 10.1016/S0167-4781(00)00296-7, 11267653.
50. Gardino AK, Smerdon SJ, Yaffe MB. Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Semin Cancer Biol 2006, 16:173-182. 10.1016/j.semcancer.2006.03.007, 16678437.
51. Seimiya H, Sawada H, Muramatsu Y, Shimizu M, Ohko K, Yamane K, Tsuruo T. Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO J 2000, 19:2652-2661. 10.1093/emboj/19.11.2652, 212742, 10835362.
52. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature 2011, 469:336-342. 10.1038/nature09783, 3073349, 21248840.
53. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63. 10.1038/nature07228, 18668040.
54. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773. 10.1038/nature03315, 15685193.
55. Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Sakurai D, Fujimura L, Kawakami K, Chiyomaru T, Yoshino H, Enokida H, Nakagawa M, Okamoto Y, Seki N. Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). J Hum Genet 2011, 56:595-601. 10.1038/jhg.2011.66, 21753766.
56. Avissar M, Christensen BC, Kelsey KT, Marsit CJ. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 2009, 15:2850-2855. 10.1158/1078-0432.CCR-08-3131, 2669849, 19351747.
57. Harris T, Jimenez L, Kawachi N, Fan JB, Chen J, Belbin T, Ramnauth A, Loudig O, Keller CE, Smith R, Prystowsky MB, Schlecht NF, Segall JE, Childs G. Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 2012, 180:917-928. 10.1016/j.ajpath.2011.12.004, 3349885, 22234174.
58. Hui AB, Bruce JP, Alajez NM, Shi W, Yue S, Perez-Ordonez B, Xu W, O'Sullivan B, Waldron J, Cummings B, Gullane P, Siu L, Liu FF. Significance of dysregulated metadherin and microRNA-375 in head and neck cancer. Clin Cancer Res 2011, 17:7539-7550. 10.1158/1078-0432.CCR-11-2102, 22031094.
59. Wang F, Li Y, Zhou J, Xu J, Peng C, Ye F, Shen Y, Lu W, Wan X, Xie X. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol 2011, 179:2580-2588. 10.1016/j.ajpath.2011.07.037, 3204087, 21945323.
60. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008, 47:1955-1963. 10.1002/hep.22256, 18433021.
61. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, Qin YR, Guan XY. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012, 61:33-42. 10.1136/gutjnl-2011-300178, 21813472.
62. Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, Liu X, Ke Y, Si J, Zhou T. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 2010, 20:784-793. 10.1038/cr.2010.79, 20548334.
63. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136. 10.1016/0092-8674(90)90409-8, 2175676.
64. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825. 10.1016/0092-8674(93)90500-P, 8242752.
65. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A 1993, 90:3988-3992. 10.1073/pnas.90.9.3988, 46431, 8387205.
66. White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 1994, 8:666-677. 10.1101/gad.8.6.666, 7926757.
67. Helt AM, Funk JO, Galloway DA. Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J Virol 2002, 76:10559-10568. 10.1128/JVI.76.20.10559-10568.2002, 136576, 12239337.
68. Zheng ZM, Tao M, Yamanegi K, Bodaghi S, Xiao W. Splicing of a cap-proximal human Papillomavirus 16 E6E7 intron promotes E7 expression, but can be restrained by distance of the intron from its RNA 5' cap. J Mol Biol 2004, 337:1091-1108. 10.1016/j.jmb.2004.02.023, 15046980.
69. Tang S, Tao M, McCoy JP, Zheng ZM. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J Virol 2006, 80:4249-4263. 10.1128/JVI.80.9.4249-4263.2006, 1472016, 16611884.
70. Rosenberger S, De-Castro Arce J, Langbein L, Steenbergen RD, Rosl F. Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation. Proc Natl Acad Sci U S A 2010, 107:7006-7011. 10.1073/pnas.1002620107, 2872467, 20351270.
71. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008, 27:2575-2582. 10.1038/sj.onc.1210919, 2447163, 17998940.
72. Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, Broker TR, Meyers C, Chow LT, Zheng ZM. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 2009, 15:637-647. 10.1261/rna.1442309, 2661824, 19258450.
73. Au Yeung CL, Tsang TY, Yau PL, Kwok TT. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene 2011, 30:2401-2410. 10.1038/onc.2010.613, 21242962.
74. Shi M, Du L, Liu D, Qian L, Hu M, Yu M, Yang Z, Zhao M, Chen C, Guo L, Wang L, Song L, Ma Y, Guo N. Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol 2012, 228:148-157. 10.1002/path.3997, 22287315.
75. Melar-New M, Laimins LA. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J Virol 2010, 84:5212-5221. 10.1128/JVI.00078-10, 2863797, 20219920.
76. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008, 40:43-50. 10.1038/ng.2007.30, 2628762, 18066065.
77. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26:745-752. 10.1016/j.molcel.2007.05.010, 1939978, 17540599.
78. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533. 10.1038/nature08199, 19626115.
79. Brosh R, Shalgi R, Liran A, Landan G, Korotayev K, Nguyen GH, Enerly E, Johnsen H, Buganim Y, Solomon H, Goldstein I, Madar S, Goldfinger N, Borresen-Dale AL, Ginsberg D, Harris CC, Pilpel Y, Oren M, Rotter V. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol 2008, 4:229. 2600669, 19034270.
80. Nuovo GJ, Wu X, Volinia S, Yan F, di Leva G, Chin N, Nicol AF, Jiang J, Otterson G, Schmittgen TD, Croce C. Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection. Diagn Mol Pathol 2010, 19:135-143. 10.1097/PDM.0b013e3181c4daaa, 20736742.
81. Zheng ZM, Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 1809, 2011:668-677.
82. Meyers C, Frattini MG, Hudson JB, Laimins LA. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992, 257:971-973. 10.1126/science.1323879, 1323879.
83. McCance DJ, Kopan R, Fuchs E, Laimins LA. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci U S A 1988, 85:7169-7173. 10.1073/pnas.85.19.7169, 282145, 2459699.
84. Jung HM, Phillips BL, Patel RS, Cohen DM, Jakymiw A, Kong WW, Cheng JQ, Chan EK. Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) in Oral Cancer. J Biol Chem 2012, 287:29261-29272. 10.1074/jbc.M112.366518, 3436145, 22761427.
85. Ragin CC, Reshmi SC, Gollin SM. Mapping and analysis of HPV16 integration sites in a head and neck cancer cell line. Int J Cancer 2004, 110:701-709. 10.1002/ijc.20193, 15146560.
86. Kelley ML, Keiger KE, Lee CJ, Huibregtse JM. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J Virol 2005, 79:3737-3747. 10.1128/JVI.79.6.3737-3747.2005, 1075713, 15731267.
87. Jakymiw A, Patel RS, Deming N, Bhattacharyya I, Shah P, Lamont RJ, Stewart CM, Cohen DM, Chan EK. Overexpression of dicer as a result of reduced let-7 MicroRNA levels contributes to increased cell proliferation of oral cancer cells. Genes Chromosomes Cancer 2010, 49:549-559. 10.1002/gcc.20765, 2859695, 20232482.
88. Cattani P, Siddu A, D'Onghia S, Marchetti S, Santangelo R, Vellone VG, Zannoni GF, Fadda G. RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus. J Clin Microbiol 2009, 47:2136-2141. 10.1128/JCM.01733-08, 2708475, 19403762.
89. Wege H, Chui MS, Le HT, Tran JM, Zern MA. SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Res 2003, 31:E3-E13. 140528, 12527792.
90. Soo Hoo L, Zhang JY, Chan EKL. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002, 21:5006-5015. 10.1038/sj.onc.1205625, 12118381.
91. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, Chan EK. CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther 2010, 10:694-699. 10.4161/cbt.10.7.12895, 3230513, 21068540.